Genmab — Oktober 2020

kkjoel

Ok, den tog EL sig af

E_L

good morning

kkjoel

And good mornings to The ELectrician I didn't have a target from GS, so it must be quite an old (and ridiculously low) one, 1,112?! But classically executed, none the less: buy, buy, buy yourself (having a target of 1,112 and a price of 2,200.. so that makes a lot of sense) - THEN recommend buy to all others.

kkjoel

Must be extremely positive for GEN 2day w GS recommendation. AND NBI up 0,5% yday. Let'
s see...

kkjoel

All right, they didn't recommend buy, but they more than doubled the TP. Same, same....

Solsen

Har valgt at reducere lidt på GS analysen, der har holdt hånden under Genmab. Det ligner en blodig dag med lockdowns trusler og smittetal der skræmmer.

Solsen

Men håber at Genmab stiger

SEACOP

Peak March 2021. https://financhill.com/stock-forecast/GMAB-stock-prediction

E_L

Novartis (NVS) CEO, Vas Narasimham on Q3 2020 Results - Earnings Call Transcript https://seekingalpha.com/article/4381882-novartis-nvs-ceo-vas-narasimham-on-q3-2020-results-earnings-call-transcript?part=single

Bulder

Nice: "If you look at some of the estimates on what the B-cell market could look like over the next 10 years, there are some estimates that point us to 35% to 40% of the market."

Solsen

Thats a lot

Bulder

Lad os antage at det svarer til 4 mia $. 10% heraf er 400 mio $.

E_L

PRAC agenda: 5.3.4. Carfilzomib - KYPROLIS (CAP) - EMEA/H/C/003790/II/0045, Orphan
Applicant: Amgen Europe B.V.

Scope: Extension of existing indication to include combination of Kyprolis (carfilzomib) with
daratumumab and dexamethasone. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the
SmPC are updated. The package leaflet is updated in accordance
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP